

EASL School of Hepatology 2021

Liver Pathology

“inflammatory liver diseases; new developments, new challenges!”

With endorsement of the European Society of Pathology (ESP)

15 and 16 October 2021

Course organizers:

Valérie Paradis (Paris, France)

Peter Schirmacher (Heidelberg, Germany)

Joanne Verheij (Amsterdam, The Netherlands)

Location: Amsterdam, The Netherlands

Faculty:

Ulrich Beuers (Amsterdam, The Netherlands)

Joep de Bruijne (Utrecht, The Netherlands)

Minneke Coenraad (Leiden, The Netherlands)

Otto van Delden (Amsterdam, The Netherlands)

Joost Drenth (Nijmegen, The Netherlands)

Onno Holleboom (Amsterdam, The Netherlands)

Jesper Kers (Amsterdam en Leiden, The Netherlands)

Rob de Man (Rotterdam, The Netherlands)

Valérie Paradis (Paris, France)

Cyriel Ponsioen (Amsterdam, The Netherlands)

Peter Schirmacher (Heidelberg, Germany)

Bart Takkenberg (Amsterdam, The Netherlands)

Joanne Verheij (Amsterdam, The Netherlands)

The role of the liver biopsy in inflammatory liver diseases has undergone major changes in the past decennia. Clinical tests, non-invasive techniques and imaging improved. Indication for liver biopsies changed and, consequently, the number of liver biopsies decreased for some indications, like viral hepatitis. For many liver diseases, such as NAFLD, liver biopsy represents the gold standard. Still, the majority of patients with NAFLD will never undergo a biopsy. A liver biopsy is part of the initial diagnostic work-up for the diagnosis of auto-immune hepatitis. For biliary diseases, however, a biopsy is not required for diagnosis, but histology may be very informative in these patients to rule out concomitant auto-immune hepatitis or other liver diseases. New drugs, including immunotherapeutic agents in the field of oncology, may be associated with variable liver toxicities that we encounter and discover these days. Infectious diseases of the liver are one of the most prevalent health problems worldwide, but biopsy strategies are variable and changing.

When a liver biopsy is considered for diagnostic purposes, the major question is the benefit of the information obtained from the biopsy, including the added value of the liver biopsy for the different diseases in relation to non-invasive tests. These considerations are the main focus of this EASL School. The participants are invited to provide grading and staging of the different liver diseases and relevant scoring systems will be discussed.

Each disease will be tackled from a clinical point of view and from the perspective of the pathologist focusing on criteria for diagnosis and possible pitfalls. The interaction between all these partners is key, during this course and in daily practice!

Relevant literature (pre-reading material, including scientific articles) will be provided to the participants before the meeting. Hand-outs will be provided after the course.

Clinical cases, including digitalized biopsies will be available before the start of the School.

During the meeting, complementary clinical and pathological talks will address relevant topics with a general clinical introduction and followed by plenary discussions.

Clinical cases will be discussed per theme to illustrate the importance of clinico-pathological correlation, to discuss the role of the liver biopsy and the grading and staging of the different liver diseases.

Workshops, including slides sessions, will be planned to illustrate the morphological spectrum of 'inflammatory liver diseases'.

Participants can supply interesting cases from their own institution (that should be made available before the start of the course for discussion during the workshop sessions).

A quiz application (via mobile phone) will be used to ensure interactive contribution of the participants.

Webinar

General approach of a medical liver biopsy; a pathologist point of view

Joanne Verheij

Friday 15 October 2021

Morning session:

- 8.30-9.00 Registration and coffee
- 9.00-9.30 Welcome and introduction
- 9.30-9.45 When and how to biopsy; point of view of the radiologist and hepatologist
- Ulrich Beuers / Otto van Delden*

Non-alcoholic fatty liver disease and alcoholic fatty liver disease

Chairs: Valérie Paradis and Joanne Verheij

- 9.45-10.00 Clinical summary talk non-alcoholic fatty liver disease
- Onno Holleboom*
- 10.00-10.15 Clinical summary talk alcoholic fatty liver disease
- Minneke Coenraad*
- 10.15-10.45 Coffee break
- 10.45-11.30 Interactive session “alcoholic and non-alcoholic fatty liver disease” with clinical cases, digitalized slides and plenary discussion.
- 11.30-11.45 Summary and future perspectives; role of the pathologist in NASH and ASH
- Valérie Paradis*

Viral hepatitis

Chairs: Peter Schirmacher and Valérie Paradis

11.45-12.00 Clinical summary talk viral hepatitis; overview hepatotropic viruses

Rob de Man

12.00-13.00 Lunch Break

Afternoon session:

13.00-13.45 Interactive session “viral hepatitis” with clinical cases, digitalized slides and plenary discussion.

13.45-14.00 Summary and future perspectives; role of the pathologist in viral hepatitis

Valérie Paradis

Immune mediated liver diseases

Chairs: Peter Schirmacher and Joanne Verheij

14.00-14.15 Clinical summary talk auto-immune hepatitis

Joost Drenth

14.15-14.30 Biliary diseases

Ulrich Beuers/Cyriel Ponsioen

14.30-15.00 Coffee break

15.00-16.00 Interactive session “immune mediated liver disease” with clinical cases, digitalized slides and plenary discussion.

16.00 -16.15 Summary and future perspectives; role of the pathologist in immune mediated liver diseases

Peter Schirmacher

16.15-16.30 Drinks

16.30-17.30 Workshops in small groups

4 different clinical cases will be discussed within small groups with a member of the faculty

Artificial intelligence; threat or chance for the liver pathologist?

17.30-18.00 Artificial Intelligence in Pathology

Jesper Kers

Saturday 16 October 2021

Morning session:

Toxic hepatitis

Chairs: Valérie Paradis and Peter Schirmacher

8.30-8.45 Clinical summary talk toxic liver disease

Joep de Bruijne

8.45-9.30 Interactive session “toxic liver disease” with clinical cases, digitalized slides and plenary discussion.

9.30-9.45 Summary and future perspectives; role of the pathologist in toxic hepatitis

Peter Schirmacher

9.45-10.15 Coffee break

Cirrhosis, terminology, grading and reversibility

Chairs: Valérie Paradis and Joanne Verheij

10.15-10.30 Clinical summary talk dynamics of liver cirrhosis and non-invasive tools

Bart Takkenberg

10.30-11.15 Interactive session “liver cirrhosis” with clinical cases, digitalized slides and plenary discussion.

11.15-11.30 Summary and future perspectives; role of the pathologist in liver cirrhosis

Joanne Verheij

11.30-12.30 Two group presentations (20 min) of the clinical cases, prepared on Friday and plenary discussion (20 minutes)

12.30-13.30 Lunch

Afternoon session:

13.30-14.30 Two group presentations (20 min) of the clinical cases, prepared on Friday and plenary discussion (20 minutes)

14.30-14.45 Final clinicopathology talk

Peter Schirmacher

14.45-15.00 Post-assessment test

15.00 Farewell with drinks